Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
NCT07898696
Summary
The REFLOW AMI Trial aims to determine whether prophylactic high-dose intracoronary adenosine reduces slow-flow or no-reflow (SNR) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Slow-flow or no-reflow occurs when blood flow to the heart muscle remains reduced despite treatment of the blocked coronary artery. This complication can lead to greater heart muscle damage and worse clinical outcomes. The study will evaluate a protocol involving 200 micrograms of intracoronary adenosine administered before each balloon or stent inflation during PPCI. Researchers will compare outcomes with standard PPCI care without prophylactic adenosine. The main questions the study aims to answer are: * Does prophylactic intracoronary adenosine reduce the incidence of slow-flow or no-reflow after PPCI? * Does the protocol improve post-PCI coronary blood flow, assessed by TIMI flow grade and myocardial blush grade? * What are the rates of major adverse cardiovascular events (MACE) during hospitalization and at 30 days? * Does the protocol affect left ventricular ejection fraction (LVEF) at discharge and at 30 days? * Does the protocol improve functional capacity at 30 days, assessed by the six-minute walk test? * Is the prophylactic adenosine protocol safe? Participants will undergo PPCI according to their assigned study group and will be assessed for angiographic outcomes, safety events, and clinical outcomes during hospitalization and follow-up, including at 30 days.
Eligibility
Inclusion Criteria; * 18 years and older of either gender * Diagnosis of STEMI * Undergoing primary PCI Exclusion Criteria: * Cardiogenic shock * Severe hypotension (SBP \<90 mmHg) * Bradycardia with HR \< 50 bpm without pacemaker * Known hypersensitivity to adenosine * Severe asthma or COPD with bronchospasm * Pregnancy * Spontaneous coronary artery dissection (SCAD) * Myocardial Infarction in non - obstructive coronaries (MINOCA) * Lesions unable to be crossed with coronary wire
Conditions2
Interventions1
Related trials
- BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome. — Vastra Gotaland Region
- Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients — Rashid Latif Medical College
- Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses — Region Skane
- Adenosine vs Diltiazem for Treatment of SVT in the ED — Anne E. Zepeski
- Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions — Weill Medical College of Cornell University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07898696